Dormandy J A, Goyle K B, Reid H L
Lancet. 1977 Mar 19;1(8012):625-6. doi: 10.1016/s0140-6736(77)92059-1.
Fifteen patients with severe intermittent claudication were treated by therapeutic defibrination with subcutaneous injections of ancrod for 5 weeks. Mean plasma-fibrinogen was maintained below 50% of the initial value throughout the treatment period. This reduction in plasma-fibrinogen was accompanied by a parallel fall in whole-blood viscosity and a pronounced clinical improvement. Objective measurements showed maximum benefit on the 21st day of treatment, when the mean resting ankle/arm pressure index had increased by 37%, the post-exercise pressure index had increased by 50%, and the time taken for the pressure index to return to a resting value after a constant exercise had decreased by 33%. (The claudication-count had increased by 59%).
15例严重间歇性跛行患者接受了皮下注射抗栓酶进行治疗性去纤维蛋白治疗,为期5周。在整个治疗期间,血浆纤维蛋白原平均维持在初始值的50%以下。血浆纤维蛋白原的这种降低伴随着全血粘度的相应下降以及明显的临床改善。客观测量显示,在治疗第21天时获益最大,此时平均静息踝/臂压力指数增加了37%,运动后压力指数增加了50%,在进行恒定运动后压力指数恢复到静息值所需的时间减少了33%。(间歇性跛行次数增加了59%)